NUNZIA PHARMACEUTICAL Co Overview
Industry: Drug Manufacturers Specialty & Generic
Sector: Healthcare
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorders. It offers its products through wholesalers, as well as through its website nunziapharma.com. The company was formerly known as Arizona Gold and Onyx Mining Company and changed its name to Nunzia Pharmaceutical Company in February 2018. Nunzia Pharmaceutical Company was incorporated in 1986 and is based in Long Beach, California.
NUNZIA PHARMACEUTICAL Co is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review NUNZIA PHARMACEUTICAL Co in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
NUNZIA PHARMACEUTICAL Co Competitors
NUNZIA PHARMACEUTICAL Co operates in the Drug Manufacturers Specialty & Generic industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans